Announcements Trials
Browse Landscape

Status

No longer available 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 99Observational 2Expanded_access 2

Sponsor

Cancer Type

Breast 2

Conditions

Triple Negative Breast Neoplasms 2

Interventions

3-Iodobenzylguanidine 9Amifampridine 6nilotinib 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3fludarabine phosphate 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × veliparib × Clear all
NCT03123211 2022-05-24

Expanded Access to Veliparib

AbbVie

No longer available
Breast

Triple Negative Breast Neoplasms

NCT02985658 2021-07-21

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

University of Washington

No longer available
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡